证券代码：002099 证券简称：海翔药业 公告编号：2023-054 二零二三年十月三十一日 浙江海翔药业股份有限公司（以下简称"公司"）于 2023 年 10 月 30 日召 开第七届董事会第六次会议，会议审议通过了《关于高级管理人员职务调整的议 案》，同意聘任姚冰先生为公司财务总监（后附简历），任期自本次董事会审议 通过之日起至公司第七届董事会届满之日止。 原财务总监王晓洋女士因职务调整，不再兼任公司财务总监职务，仍担任公 司董事、副总经理、董事会秘书职务，其职务调整不会影响公司相关工作正常开 展。王晓洋女士担任公司财务总监期间恪尽职守、勤勉尽责，公司董事会对王晓 洋女士在担任财务总监期间所做的贡献表示由衷的感谢！ 特此公告。 浙江海翔药业股份有限公司 董 事 会 浙江海翔药业股份有限公司 关于高级管理人员职务调整的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 附：简历 姚冰先生，中国国籍，无境外永久居留权，生于 1982 年 11 月，中共党 员，特许金融分析师，澳洲注册会计师。北京大学光华管理学院工商管理硕 士，中国外交学院外交学专业硕士。2 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、外汇套期保值业务基本情况概述 浙江海翔药业股份有限公司（以下简称"公司"）于 2023 年 4 月 21 日、2023 年 5 月 15 日分别召开了第七届董事会第二次会议和 2022 年年度股东大会，审议 通过了《关于开展外汇套期保值业务的议案》，同意公司及控股子公司使用不超 过 6 亿美元（其他币种按当期汇率折算成美元汇总）开展外汇套期保值业务。具 体内容详见公司 2023 年 4 月 25 日在巨潮资讯网及《证券时报》、《证券日报》、 《上海证券报》刊登的《关于开展外汇套期保值业务的公告》（公告编号：2023- 012）。 公司遵循锁定汇率风险原则，不做投机性、套利性的交易操作。以锁定汇率、 锁定成本为原则进行外汇套期保值业务，通过锁定的汇率与客户的报价相结合， 达到规避经营风险的目的。现将有关进展情况说明如下： 证券代码：002099 证券简称：海翔药业 公告编号：2023-055 浙江海翔药业股份有限公司 关于开展外汇套期保值业务的进展公告 计），其中公司尚未完成交割的外汇套期保值业务产生的公允价值 ...

浙江海翔药业股份有限公司 关于获得药品注册证书的公告 证券代码：002099 证券简称：海翔药业 公告编号：2023-051 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司（以下简称"公司"）于近日收到国家药品监 督管理局核准签发的泮托拉唑钠肠溶片（20mg、40mg）的《药品注册证书》。 现将相关情况公告如下： 一、药品基本情况 药品名称：泮托拉唑钠肠溶片 剂型：片剂 规格：20mg、40mg 申请事项：药品注册（境内生产） 注册分类：化学药品 4 类 上市许可持有人：浙江海翔药业股份有限公司 生产企业：浙江海翔药业股份有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本 品符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品相关信息 泮托拉唑钠肠溶片是第三代新型质子泵抑制剂，适用于活动性消化性溃疡 (胃、十二指肠溃疡)、反流性食管炎和卓艾氏综合症。与克拉霉素和阿莫西 林，或克拉霉素和甲硝唑，或阿莫西林和甲硝唑配伍用能够根除幽门螺杆菌感 染，以减少该微生物感染所致的十二指肠溃疡与胃溃疡的复发。 据米内 ...

证券代码：002099 证券简称：海翔药业 公告编号：2023-050 浙江海翔药业股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 3、公司通过函件问询方式对公司控股股东、实际控制人针对相关事项进行 了核实，公司控股股东、实际控制人不存在关于应披露而未披露的重大事项， 也不存在处于筹划阶段的重大事项； 4、股票异动期间，公司控股股东、实际控制人不存在买卖公司股票的行 为。 三、关于不存在应披露而未披露信息的说明 本公司董事会确认，公司目前没有任何根据《深圳证券交易所股票上市规 则》等有关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、意 向、协议等；董事会也未获悉公司有根据《深圳证券交易所股票上市规则》等 有关规定应予以披露而未披露的、对公司股票及其衍生品种交易价格产生较大 影响的信息；公司前期披露的信息不存在需要更正、补充之处。 四、风险提示 1、公司不存在违反信息公平披露的情形。 浙江海翔药业股份有限公司（以下简称"公司"）股票（证券简称：海翔 药业，证券代码：002099） ...

证券代码：002099 证券简称：海翔药业 公告编号：2023-049 浙江海翔药业股份有限公司 关于为合并报表范围内子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、担保情况概述 浙江海翔药业股份有限公司（以下简称"公司"）分别于 2023 年 4 月 21 日召开了第七届董事会第二次会议,2023 年 5 月 15 日召开了 2022 年年度股东 大会，审议通过了《关于调整为合并报表范围内子公司提供担保额度及期限的 议案》，同意为合并报表范围内子公司港翔国际控股（香港）有限公司（以下 简称"香港港翔"）提供不超过人民币 20,000 万元（或等值外币）担保额度。 具体详见公司于 2023 年 4 月 25 日在《证券时报》、《证券日报》、《上海证 券报》和巨潮资讯网（www.cninfo.com.cn）上披露的《关于调整为合并报表范 围内子公司提供担保额度及期限的公告》（公告编号：2023-013）。 二、担保进展情况 2、担保方式：连带责任担保。 3、担保范围：贷款、授信或其他银行融资、融通票据、财务协助、衍生品 交易等。 4 ...

证券代码：002099 证券简称：海翔药业 浙江海翔药业股份有限公司投资者关系活动记录表 编号：2023-005 特定对象调研 □分析师会议 媒体采访 □业绩说明会 投资者关系 □新闻发布会 □路演活动 活动类别 □现场参观 □投资者接待日活动 其他 电话会议 参与单位名称 国泰基金、华安基金、华宝基金、金信基金、民生加银、人 及人员姓名 保养老、泰康资产、泰康基金、中邮基金 时间 2023年 9月 26 日-2023 年 9月 27 日 地点 线上电话会议 董事会秘书：王晓洋 上市公司接待 证券事务代表：蒋如东 人员姓名 1、公司多肽平台项目进展情况？ 答：公司基于客户需求介入多肽领域，并逐步搭建多肽 平台，已针对 GLP-1/GIP 药物产业链开发了数个配套产品技 术工艺。公司部分产品进展较快，拟配套原研产业链，目前 已完成商业化生产备货，正与客户沟通确认订单细节。待商 业化订单落地后，公司将正式切入原研药企配套产业链，为 未来深化合作奠定坚实的基础。 投资者关系 2、公司切入多肽项目的契机是什么？ ...

证券代码：002099 证券简称：海翔药业 公告编号：2023-048 浙江海翔药业股份有限公司 关于公司通过药品 GMP 符合性检查的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 企业名称：浙江海翔药业股份有限公司； 生产地址：浙江省台州市椒江区外沙支路 100 号； 检查范围：片剂； 生产车间生产线：F01 车间，F01-1 片剂生产线； 检查时间：2023 年 08 月 24 日至 2023 年 08 月 26 日； 检查结论：依据《药品管理法》（2019 年修订）及药品生产监督管理的有关 要求对浙江海翔药业股份有限公司进行药品生产质量管理规范符合性检查和审 核，符合《药品生产质量管理规范》（2010 年修订）。 二、对公司的影响及风险提示 公司本次获得片剂 GMP 符合性检查通过的结果，表明公司相关片剂生产线 符合 GMP 要求，将有利于提升产品质量和生产能力，为伏格列波糖片等产品后 续参与集采竞标和国内销售开拓奠定坚实基础。 近日，浙江海翔药业股份有限公司（以下简称"公司"） 从浙江省药品监 督管理局网站获悉药品 GMP 符合性检查结果公告（ ...

证券代码:002099 证券简称:海翔药业 | --- | --- | |-------------------------|---------------------| | | | | 投资者关系 活动类别 | □新闻发布会 | | | 其他 电话会议 | | | | | 参与单位名称 及人员姓名 | | | | 中昂国际、中信建投 | | 时间 2023 | 年 8 月 30 日 | | 地点 线上电话会议 | | | 上市公司接待 | | | 人员姓名 | 证券事务代表:蒋如东 | 一、公司基本情况介绍 2023 年半年度,公司实现营业收入 11.96 亿元,同比下 降 18.49%;扣除非经常性损益的净利润 0.67 亿元,同比下 降 57.77%。年初以来,人民币兑美元汇率持续大幅波动,受 此影响公司开展的外汇套期保值业务产生的投资收益与公允 价值变动损益及汇兑收益合计亏损 5,645.97 万元,对本期归 投资者关系 属于上市公司股东的净利润产生较大影响。 活动主要 报告期内,医药板块实现营业收入 8.74 亿元,占总营收 内容介绍 的 73%,收入结构进一步优化提升。医药总体销售量保持稳 健增长 ...

Financial Performance - Total assets increased to CNY 6,742,814,141.75, up from CNY 6,167,246,307.65, representing a growth of approximately 9.3% year-over-year[6] - Cash and cash equivalents at the end of the period reached CNY 1,609,820,536.78, compared to CNY 1,466,195,705.17, marking an increase of about 9.8%[12] - Net cash flow from operating activities was CNY 109,489,426.92, down from CNY 210,140,712.99, reflecting a decrease of approximately 48%[13] - Revenue from sales of goods and services received cash of CNY 886,042,330.28, a decline from CNY 957,849,360.44, indicating a decrease of about 7.5%[12] - Total liabilities increased to CNY 2,301,293,240.13, up from CNY 1,686,913,265.98, which is an increase of approximately 36.5%[6] - The company reported a profit distribution of -161,871,525.30[34] - The company reported a non-current asset disposal gain of ¥10,007,204.71[200] - Government subsidies recognized in the current period amounted to ¥7,677,596.17, closely related to the company's normal business operations[200] - The company experienced a loss of ¥65,558,104.56 from effective hedging activities not related to normal business operations[200] Cash Flow and Financing - The company reported a net cash outflow from investing activities of CNY -8,242,137.19, compared to CNY -672,379,825.43 in the previous period, showing a significant improvement[13] - Cash inflow from financing activities totaled CNY 1,334,157,300.00, compared to CNY 1,024,619,111.11, representing an increase of approximately 30.3%[13] - The company’s short-term borrowings rose to CNY 443,225,965.96 from CNY 197,210,132.90, reflecting an increase of about 125%[6] Inventory and Receivables - The company’s inventory decreased to CNY 23,441,799.95 from CNY 47,505,609.20, a reduction of approximately 50.7%[6] - The company’s other receivables increased significantly to CNY 1,401,789,909.48 from CNY 682,970,726.85, indicating a growth of about 105.5%[6] Financial Reporting and Compliance - The financial statements were approved for external release on August 28, 2023[38] - The company operates on a 12-month cycle for asset and liability liquidity classification[40] - The company has established a comprehensive financial reporting framework based on the parent company and its subsidiaries[42] - The board of directors and supervisors guarantee the accuracy and completeness of the semi-annual report, with no false records or misleading statements[188] - The financial report is signed and stamped by the legal representative and accounting personnel, ensuring compliance with regulatory requirements[180] Accounting Policies and Practices - The company recognizes financial assets and liabilities based on specific criteria, including fair value measurement and amortized cost[46] - The company has a policy for foreign currency business translation, with specific rates applied to various financial statement components[45] - The company has a structured approach to financial asset transfer recognition and measurement[48] - The company maintains a focus on ensuring accurate financial reporting in accordance with accounting standards[39] - The company has a defined method for handling financial liabilities, including those related to credit risk changes[46] - The company measures expected credit losses based on the risk of default weighted average of financial instruments[68] - The company uses a simplified measurement method to assess expected credit losses for receivables and contract assets[72] - The company applies a three-stage model to measure expected credit losses for financial instruments[57] - The company recognizes the difference between the carrying amount of transferred financial assets and the consideration received in current profits when derecognition conditions are met[64] - The company recognizes employee benefits as service costs and includes them in current profits or related asset costs[51] - The company assesses credit risk for financial instruments at each balance sheet date to determine if there has been a significant increase in credit risk since initial recognition[70] - The company recognizes short-term employee compensation as liabilities during the accounting period in which services are provided[66] - The company recognizes lease liabilities at the present value of unpaid lease payments, using the internal rate of return or incremental borrowing rate as the discount rate[35] - The estimated credit loss rates for accounts receivable are 5% for within 1 year, 30% for 1-2 years, 80% for 2-3 years, and 100% for over 3 years[85] - Long-term prepaid expenses are amortized over a period exceeding 1 year, with any unamortized balance recognized in the current period if the expenses do not benefit future periods[89] - Contract liabilities are recognized based on the relationship between the performance obligations and customer payments, with net amounts presented in the balance sheet[90] - The company accounts for employee benefits under defined contribution plans by recognizing the payable amount as a liability during the service period[92] - The company measures defined benefit plan obligations using actuarial assumptions and discounts them to present value, recognizing service costs and interest expenses in the current period[93] - The company recognizes contract costs directly related to obtaining contracts as assets, amortized based on the revenue recognition of related goods or services[98] - The initial investment cost for long-term equity investments is based on the book value of the acquired equity at the merger date, adjusted for any differences in capital reserves[100] - The company applies a perpetual inventory system for inventory management[96] - Inventory is measured at the lower of cost and net realizable value, with provisions for inventory write-downs made when costs exceed net realizable values[106] - The company capitalizes borrowing costs for qualifying assets during construction or production, but suspends capitalization if there is a significant interruption[121] - The company uses the straight-line method for depreciation of right-of-use assets, determining the period based on the lease term or the remaining useful life of the asset[123] - The company assesses whether investments are classified as joint control or significant influence based on decision-making power and control over financial and operational policies[124] - For long-term equity investments, the initial investment cost is determined based on the fair value of the consideration paid on the acquisition date[125] - The company recognizes impairment losses for contract-related assets when their carrying amount exceeds the expected recoverable amount[111] - The company applies the cost method for long-term equity investments in controlled entities and the equity method for joint ventures and associates[128] - The company recognizes gains or losses on the disposal of equity investments based on the difference between the consideration received and the carrying amount of the investment[129] Strategic Initiatives and Market Position - The company aims to be a trusted pharmaceutical enterprise in China, focusing on excellence in its operations[187] - The semi-annual report emphasizes the company's commitment to environmental and social responsibilities[191] - The company has not disclosed any new product launches or technological advancements in this report[191] - There is no mention of market expansion or mergers and acquisitions in the current report[191] - The company has confirmed that it meets the conditions for government subsidies, which will be recognized as deferred income[171] - The company primarily exports pharmaceutical products, with sales mainly denominated in USD, which exposes it to exchange rate fluctuations against RMB, impacting revenue and profitability[144] - The company is closely monitoring policy changes in the pharmaceutical industry, particularly related to centralized procurement, to mitigate operational risks[160] - The company will actively respond to international market changes and expand its domestic market presence to stabilize its international market position[144] - The company has implemented measures to hedge against exchange rate risks, including the use of currency derivatives[144] - The company has established a pricing adjustment mechanism in contracts to protect against significant exchange rate fluctuations[144] Shareholding and Dividends - The company reported a total shareholding of 642,782,587 shares held by the actual controller, Mr. Wang Yunfu, representing 73.20% of Donggang Industrial Group[185] - The company plans not to distribute cash dividends, issue bonus shares, or increase capital from reserves[189]

单位：人民币万元 浙江海翔药业股份有限公司 2023年半年度非经营性资金占用及其他关联资金往来 情况汇总表 | 非经 | 营性 | 资金 | 占用 | | | | | 占用 | 资金 | | 方名 称 | 占用 方与 关联 | 上市 公司 关系 | 的 上市 | 公司 核算 的 会计 科目 | 20 23年 期初 金余 额 | 占用 资 2023 计发 | 年半 年度 资金 生额 （不含 | 占用 累 利息 ） | 2023 年半 年度 占 用资 金的 利息 （如 有） | 20 23年 半年 度偿 计发 生金 额 | 还累 2023 年半 资金 | 年度 期末 占用 余额 | 占用 形成 原因 | | 占用 性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 控股 股东 、实 | 际控 | 制人 及其 ● | | 附属 企 ...